Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 10/20 | 0.84 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.84 |
| ▸ | SRC | P12931 | 2/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.84 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.84 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.84 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.84 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.84 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.84 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.84 |
| ▸ | LDHA | P00338 | 1/20 | 0.84 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.84 |
| ▸ | FBP1 | P09467 | 1/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.84 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.84 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.84 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835414 | 0.93 | P2RY1 (0.86) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL2512522 | 0.92 | P2RY1 (0.96) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL14478782 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Vidarabine Phosphate SCHEMBL144996 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL13374692 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL18785114 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL5588 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL2683103 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL15646670 | 0.92 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| SCHEMBL3046222 | 0.92 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530408-B2 | Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate | MESO SCALE TECHNOLOGIES LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-20100048485-A1 | SUBSTRATES OF N-END RULE UBIQUITYLATION AND METHODS FOR MEASURING THE UBIQUITYLATION OF THESE SUBSTRATE | MESO SCALE TECHNOLOGIES LLC (US) | 2010-02-25 | — | — | US | disclosed |
| US-7608682-B2 | Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates | MESO SCALE TECHNOLOGIES LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7217523-B2 | Nucleoside phosphoramidates and nucleoside phosphoramidases | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060014193-A1 | Nucleoside phosphoramidates and nucleoside phosphoramidases | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-01-19 | — | — | US | disclosed |
| US-20040137597-A1 | Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates | MESO SCALE TECHNOLOGIES LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004042352-A2 | SUBSTRATES OF N-END RULE UBIQUITYLATION AND METHODS FOR MEASURING THE UBIQUITYLATION OF THESE SUBSTRATES | MESO SCALE TECHNOLOGIES, LLC (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048485-A1 | SUBSTRATES OF N-END RULE UBIQUITYLATION AND METHODS FOR MEASURING THE UBIQUITYLATION OF THESE SUBSTRATE | STUB1, UBR4, UBE3A | P2RY1 4682/4885P2RY2 4813/4885SRC 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.